NCT06507683View on ClinicalTrials.gov

Evaluate the Efficacy and Safety of Radiotherapy Combined With Ripretinib in the Treatment of Unresectable Advanced GIST

NARecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 28, 2024

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions
Gastrointestinal Stromal Tumors
Interventions
RADIATION

simultaneous integrated boost intensity-modulated radiation therapy combined with ripretinib

"A cumulative radiation dose of 50 to 70 Gy is administered in 25-30 fractions, 5 fractions per week, to the target lesion(s).~ripretinib: oral 150mg QD"

Trial Locations (1)

400016

RECRUITING

The First Affiliated Hospital of Chongqing Medical University, Chongqing

All Listed Sponsors
collaborator

Peking University Cancer Hospital & Institute

OTHER

lead

First Affiliated Hospital of Chongqing Medical University

OTHER